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ABSTRACT
Objectives We aimed to clarify the prevalence, 
indications, analgesic comedications and complications 
of prescription opioid use in patients presenting to a large 
emergency department (ED).
Design Retrospective chart review.
Setting Large, interdisciplinary ED of a public hospital.
Participants All patients aged ≥18 years presenting 
between 1 January 2017, and 31 December 2018, with 
documentation on medication were included.
Interventions None.
Primary and secondary outcome measures Prevalence 
rates for prescription opioid use and its indication. 
Prevalence of analgesic comedications in prescription 
opioid users. Hospitalisation rate, 72 hours ED 
reconsultation rate, 30- day rehospitalisation rate, in- 
hospital mortality.
Results A total of 26 224 consultations were included 
in the analysis; 1906 (7.3%) patients had prescriptions 
for opioids on admission to the ED. The main indications 
for opioid prescriptions were musculoskeletal disease in 
1145 (60.1%) patients, followed by neoplastic disease 
in 374 (19.6%) patients. One hundred fifty- four (8.2%) 
consultations were directly related to opioid intake, and 
50.1% of patients on opioids also used other classes of 
analgesics. Patients on prescription opioids were older (76 
vs 62 years, p<0.0001) and female individuals were over- 
represented (58 vs 48.9%, p<0.0001). Hospitalisation rate 
(78.3 vs 49%, p<0.0001), 72 hours ED reconsultation rate 
(0.8 vs 0.3%, p=0.004), 30- day rehospitalisation rate (6.2 
vs 1.5%, p<0.0001) and in- hospital mortality (6.3 vs 1.6%, 
p<0.0001) were significantly higher in patients with opioid 
therapy than other patients. In 25 cases (1.3%), admission 
to the ED was due to opioid intoxication.
Conclusions Daily prescription opioid use is common 
in patients presenting to the ED. The use of prescription 
opioids is associated with adverse outcomes, whereas 
intoxication is a minor issue in the studied population.
INTRODUCTION
Opioids are widely used in ambulatory and 
hospitalised patients, but there is concern 
regarding their liberal prescription before 
alternative approaches have proven ineffec-
tive.1 The three major concerns are: creating 
dependency, misuse of dispensed drugs and 
adverse events. Although short- term use 
seems to be unlikely to cause dependency,2 
there is evidence that opioid prescriptions 
in the emergency department (ED) can lead 
to dependency in susceptible patients.3–5 
Considering the recent increased prevalence 
of prescription opioid analgesics in the USA, 
opioid misuse is a major concern.6 In Europe, 
prescription opioids are increasingly used, 
but with 8967 defined daily doses (DDD) per 
million inhabitants in Europe (11 850 for 
Switzerland) compared with 16 491 DDD in 
the USA in 2016, their prevalence is lower in 
Europe than the USA.7 Data on prescription 
opioid misuse in Europe are scarce. Kalkman 
et al studied opioid misuse in the Nether-
lands and found a prevalence of 5.6 per 
100 000 inhabitants in 2015,8 whereas data 
from the USA showed a prevalence of 22.1 
per 100 000 inhabitants in 2013.9 In Canada, 
opioid overdosing increased in the past 10 
years, reaching 15.6 per 100 000 in 2016–
2017.10 The differences between Europe and 
the USA are especially pronounced when 
comparing opioid- related deaths; although in 
Europe, deaths were stable at approximately 
1.2 per 100 000 inhabitants per year in 2007 
and 2016, there were 15 deaths per 100 000 
inhabitants from opioid overdose in the USA 
in 2017.8
Strengths and limitations of this study
 ► The large data set provides high power.
 ► First European data on individual dosages and indi-
cations of prescription opioids.
 ► Potential significant selection bias due to missing 
medication data.
 ► Single- centre study; therefore, the results are not 
necessarily generalisable.
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Physicians are also confronted with other downsides 
of opioid use. Adverse events such as nausea, vertigo and 
constipation have been widely reported. Moreover, it has 
been shown that patients undergoing opioid therapy have 
significantly decreased cognitive function as measured by 
the Mini- Mental State Examination and Montreal Cogni-
tive Assessment.11 In addition, it has been found that 
patients presenting with vertigo, who were also prescribed 
opioids, were at significantly higher risk of fractures than 
patients who were not prescribed opioids.12 The inci-
dence of adverse events from opioids prescribed in the 
ED is generally low and associated with age, sex and route 
of administration.13 Another point to consider is the accu-
mulation of opioid- metabolites in patients with impaired 
renal function. Hydromorphone is considered a safer 
treatment than morphine and oxycodone.14
Most available data on prescription opioid use are from 
the USA, where the lay press, experts and even govern-
ment officials are talking about a national crisis due to 
opioid overuse. Although little data are available from 
central Europe, it is likely that there are considerable 
national discrepancies in the patterns of opioid use. To 
the best of our knowledge, no single study on the prev-
alence of prescription opioid use and its indications and 
association with the outcome from a large heterogenic 
patient collective with data from central Europe exists.
Therefore, we aimed to evaluate: (1) the prevalence of 
outpatient prescription opioid use and analgesic come-
dication in opioid users. Furthermore, we investigated 
(2) the indications and (3) the association with adverse 
outcomes of prescription opioid use in a large, hetero-
genic collective of patients presenting to the ED of a large 
public hospital.
METHODS
Study design and setting
The Department of Emergency Medicine of the Bürg-
erspital Solothurn is an interdisciplinary ED, treating 
approximately 35 000 patients per year. We performed 
a retrospective chart review of all admissions to our ED 
between 1 January 2017 and 31 December 2018. The 
study protocol is available in the appendix (online supple-
mental file 1).
Selection of participants
All patients admitted to our ED with documentation of 
home medication in their electronic patient records were 
included in the analysis. Chart reviews were performed on 
all included patients, and the data extraction form can be 
found in the appendix (online supplemental file 2). The 
following substances were labelled as opioid therapy and 
the dose per 24 hours was extracted: morphine, hydro-
morphone, fentanyl, buprenorphine, tramadol, dihydro-
codeine, levomethadone, methadone, tapentadol, tilidin, 
oxycodone and oxycodone/naloxone.
Patients younger than 18 years of age and patients who 
generally withdrew the approval to use their data for any 
scientific purposes written or verbally were excluded from 
the analysis.
Measurements
Demographic data were gathered from all included 
patients on comorbidities, current medication, indi-
cations for opioid prescriptions, reason for current 
ED consultation and relation to opioid intake, need to 
administer naloxone, need for hospitalisation, 72- hour 
ED reconsultation, hospital length of stay, mortality, pres-
ence of alcohol and/or benzodiazepine cointoxication in 
patients taking opioid analgesics presenting with opioid- 
intoxication and estimated glomerular filtration rate 
(GFR) by the CKD- EPI- Formula. Indications for opioid 
prescriptions were either categorised as ‘neoplastic 
disease’, ‘musculoskeletal’ (which comprised degenera-
tive, traumatic and autoimmune diseases of the locomotor 
system) or ‘other’. The outcomes ‘constipation’, ‘vertigo’, 
‘delirium’, ‘pain’, ‘opioid intoxication’ and ‘presentation 
due to opioid therapy’ were flagged if stated as such in the 
discharge report. Data on the duration of opioid therapy 
and the actual usage of on- demand prescriptions were 
not consistently available and thus were not analysed.
Chart reviews and data extraction were performed by 
the same three persons (BW, PB, SR), who are all trained 
medical professionals. The criteria for abstraction were 
predefined and explained in detail to the researchers. All 
cases that could not be classified clearly with the initial 
criteria were marked as ‘unclear’ and reviewed by the 
same person (BW). Apart from that, no monitoring of 
the chart abstraction was performed. We did not assess 
interobserver reliability. Data were stored in a central 
database in an anonymised fashion.
Statistical methods
Out of 1923 dosages of opioids, 94 (4,9%) were missing 
and imputed from the median doses of the respective 
opioid. In 6737 patients (25.7%), a GFR >90 was imputed 
from a normally distributed value between 91 and 130.
After completion of data collection, data were cleaned 
and outliers (>95% CI) were reconfirmed or corrected. 
Data were exported to a statistical software package 
(SPSS for Windows, V.23) for analysis. Continuous data 
are presented as the median and interquartile ranges. 
The distribution of continuous variables was assessed 
using normal plots, and logarithm transformation was 
performed when appropriate. Categorical data are 
presented as absolute counts and per cent. Between- group 
comparisons of continuous variables were performed 
using one- way ANOVA and the Bonferroni test for post 
hoc comparisons. Categorical variables were compared 
using the χ2 test or Fisher exact test. Logistic regression 
was used to explore the association of opioid intake with 
death, length of stay, 72- hour reconsultation in the ED 
and 30- day rehospitalisation. Binary logistic regression was 
used to identify risk factors for mortality, 72 hours recon-
sultation rate to the ED, 30- day rehospitalisation rate and 
overall length of stay. Based on biological plausibility and 
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to adjust for confounders, multivariable logistic regres-
sion analysis was used by entering the three predefined 
covariates age, sex and GFR into the model. A two- sided p 
value <0.05 was considered statistically significant.
Patient and public involvement
There was no patient or public involvement in the design 
or planning of the present study.
RESULTS
During the study period, 61 366 ED consultations from a 
total of 19 039 patients were recorded; 76.8% of patients 
had 1, 15.1% had 2, 4.7% had 3% and 3.3% had ≥4 
consultations. Of these, 26 224 consultations had details 
on the medication records and were thus included in the 
analysis, as shown in figure 1.
Characteristics of study participants
The median age of patients was 63 years (IQR 44–78 
years), and 49.6% of patients were female individuals; 
51.8% of patients needed hospitalisation. The 72 hours 
reconsultation rate to the ED (0.4%, 95% CI 0.29–0.43) 
and the 30- day rehospitalisation rate (1.8%, 95% CI 1.66–
1.98) were generally low, and overall mortality was 1.9%. 
The full baseline characteristics are shown in table 1.
Types, dosage and indication of prescription opioids
In this sample, 1906 patients (7.3%) were taking sched-
uled opioids with a median daily morphine equivalent 
(MEQ) of 30 mg (IQR 15–80.5 mg). The prevalence and 
median dosages of the individual opioids are shown in 
table 2. Non- opioid analgesics were used in only 50.1% of 
patients on chronic opioid analgesics.
Indications for opioid prescriptions were musculoskel-
etal in 1145 (60.1%) patients, neoplastic disease in 374 
(19.6%) and other indications in 290 (15.2%). In 340 
cases (17.8%), no indication for opioid intake could be 
identified by a detailed chart review.
Complications related to opioid intake
Falls, constipation and presence of delirium on admission 
to the ED were significantly more common in patients 
using prescription opioids. A comparison between 
patients taking scheduled opioids with patients not taking 
scheduled opioids regarding the associated complications 
is shown in table 1. One hundred fifty- four (8.2%) ED 
visits from patients on scheduled opioids were considered 
to be related to opioid intake. Twenty- five patients taking 
opioid medication were admitted due to opioid intoxi-
cation (1.3%, 95% CI 0.8–1.8); 3 of these patients had a 
cointoxication with alcohol, 9 with benzodiazepines and 
1 with both alcohol and benzodiazepines.
Intake of scheduled opioids was found to be inde-
pendently associated with the death of any cause (OR 2.76; 
95% CI 2.2–3.42), readmission to the ED within 72 hours 
(OR 2.69; 95% CI 1.52–4.76) and rehospitalisation within 
30 days (OR 3.57; 95% CI 2.87–4.44), the detailed results 
of the logistic regression are shown in table 3.
Opioid prescription in patients with impaired renal function
No difference in non- opioid analgesics use was observed 
when adjusted for the estimated glomerular filtration rate 
(eGFR). Although hydromorphone does not accumulate 
in patients with impaired renal function, it was sparsely 
used in our population. Hydromorphone was prescribed 
in only 18 patients, and no patient had an eGFR below 
30 mL/min. In contrast, 97 patients on chronic opioids 
other than hydromorphone had an eGFR between 15 
and 29 mL/min (8.1%), and 24 patients had an eGFR 
below 15 mL/min (2.0%). Of the 25 patients presenting 
with opioid intoxication, 2 had an eGFR between 15 and 
29 mL/min and 2 had an eGFR below 15 mL/min.
DISCUSSION
In the present study, we found a prevalence of 7.3% for 
prescription opioid use in patients presenting to the ED. 
The musculoskeletal disease was the main indication for 
opioid use, outnumbering neoplastic disease three times. 
The use of prescription opioids was independently asso-
ciated with 72- hour ED reconsultation, 30- day rehospital-
isation and in- hospital mortality. Only one in two patients 
using opioid medication also used non- opioid baseline 
analgesics. This study was conducted in a large population 
of ED patients from a wide spectrum of socioeconomic 
backgrounds since Swiss mandatory health insurance 
requests beneficiaries seek treatment in their province of 
residence and our hospital is the only regional provider. 
This gives a potential bias to our data, as more expensive 
private insurance lifts that limitation. Additionally, this is 
one of the first studies conducted in continental Europe.
The finding of this study that patients using prescription 
opioids are older with a female predominance is similar to 
previous findings.13 Oxycodone and fentanyl were the most 
commonly prescribed opioids. Interestingly, only approx-
imately half of patients taking prescription opioids in our 
collective also used other analgesics, as recommended by 
Figure 1 Flow diagram of patient selection and group 
allocation. Data abstraction was performed on all 26 224 
patients with detailed medication records; 2412 patients 
were excluded due to being younger than 18 years of age; 
no patient had a documented withdrawal of consent. ED, 
emergency department.
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the WHO analgesic ladder scheme. This, in addition to the 
finding that musculoskeletal pain is the primary indication 
for opioid prescription raises the question of whether opioid 
prescription practices are too permissive.
Although the present findings show that adverse events 
due to prescription opioids, especially intoxications, are 
not highly prevalent in our population, we showed that 
ED consultations due to complaints such as constipa-
tion, falls or delirium were significantly more common 
in patients on prescription opioids. These findings also 
support data from Daoust et al, where any side effects 
were reported in 79% and constipation in 38% of patients 
taking opioids in a prospective evaluation of opioid side 
effects.15 Moreover, in the present study, more 72- hour ED 
reconsultations, a higher need for hospitalisation as well 
as 30- day rehospitalisation were found in patients taking 
opioids on a regular basis. These data are supported by 
previous investigations where 53% of the ED visits for 
opioid overdose resulted in hospitalisation and 10% led 
to a near- fatal event.16 This poses a significant burden for 
EDs, hospitals and insurers.
Compared with the USA, little data on the prevalence, 
indications and potential complications of prescription 
opioids in European ED patients exist. To the best of our 
knowledge, this is the first study providing data on this 
issue from a central European collective of patients. As 
stated above, the rate of opioid misuse and opioid- related 
mortality are considerably less in Europe than in the 
USA. Additionally, more opioid- dependent patients are 
enrolled in treatment programmes in Europe.9 Our study 
reproduces results from the USA insofar as oxycodone 
and fentanyl are the most frequently used preparations7 
and musculoskeletal pain is the primary indication for 
opioid prescription.17 In view of the above, the prescrip-
tion patterns in our Swiss collective are similar to those 
reported in the USA. Previous studies have shown an 
increased rate of opioid- related complications exceeding 
a MEQ of 50 mg/d18 19 and increased mortality for doses 
Table 1 Baseline characteristics
Overall Patients with opioids Patients without opioids P value
No of patients 26 224, 100% 1906, 7.3% 24 318, 92.7%   
Age (years) 63 (IQR 44–78) 76 (IQR 59–85) 62 (IQR 42–77) <0.0001
Gender         
  Female 12 998, 49.6% 1105, 58% 11 893, 48.9% <0.0001
  Male 13 226, 50.4% 801, 42.0% 12 425, 51.1%   
Hospitalisation rate 13 583, 51.8% 1492, 78.3% 12 091, 49.7% <0.0001
Length of stay (days) 1 (IQR 1–4) 5 (IQR 1–8) 1 (IQR 1–4) <0.0001
Readmission within 72 hours 94, 0.4% 15, 0.8% 79, 0.3% 0.004
Rehospitalisation within 30 
days
478 to 1.8% 119, 6.2% 359, 1.5% <0.0001
Mortality 510, 1.9% (95% CI 1.8–2.1) 121, 6.3% (95% CI 5.3–7.4) 389, 1.6% (95% CI 1.4–1.8) <0.0001
Scheduled opioids 1906, 7.3% (95% CI 7.0–7.6)       
Use of non- opioid analgesics 5154, 19.7% 954, 50.1% 4200, 17.3% <0.0001
  Paracetamol 2794, 10.7% 569, 29.9% 2225, 9.1% <0.0001
  Metamizole 1664, 6.3% 409, 21.5% 1255, 5.2% <0.0001
  NSAIDs 2797, 10.7% 372, 19.5% 2425, 10% <0.0001
Indications for opioids         
  Malignancy   374, 19.6%     
  Musculoskeletal   1145, 60.1%     
  Other   290, 15.2%     
  Unknown   340, 17.8%     
Reasons for presentation to 
the ED
        
  Related to opioid therapy 154, 0.6% (95% CI 0.5–0.7) 154, 8.1% (95% CI 6.9–9.3) 0, 0%   
  Fall 1450, 5.5% (95% CI 5.3–5.8) 138, 7.2% (95% CI 6.1–8.4) 1312, 5.4% (95% CI 5.1–5.7) 0.001
  Constipation 704, 2.7% (95% CI 2.5–2.9) 98, 5.1% (95% CI 4.2–6.1) 606, 2.5% (95% CI 2.3–2.7) <0.0001
  Delirium 718, 2.7% (95% CI 2.5–2.9) 106, 5.6% (95% CI 4.5 –6.6) 612, 2.5% (95% CI 2.3 –2.7) <0.0001
  Vertigo 751, 2.9% (95% CI 2.7 –3.1) 58, 3.0% (95% CI 2.3–3.8) 693, 2.8% (95% CI 2.6–3.1) 0.62
eGFR (mL/min) 85 (IQR 63–107) 72 (IQR 47–93) 86 (IQR 65–107) <0.0001
ED, emergency department; eGFR, estimated glomerular filtration rate (CKD- EPI formula); NSAIDs, non- steroidal anti- inflammatory drugs.
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larger than 200 mg/d.20 The reported median MEQ in 
the USA varies from 6.019 to 53.6 mg/d.21 In context, our 
study population had a median MEQ of 30 mg/d, with 
the highest dosages for methadone. Thus, the dosages 
of opioids in the European and the US population seem 
comparable. Therefore, we assume that the current opioid 
crisis in the USA is not dose- related but due to the factors 
proposed by Fisher et al, including questionable promo-
tion campaigns of the pharmaceutical industry, increased 
patient demand for ‘effective treatment’ and permissive 
prescription practices.22 In Switzerland, on the other 
hand, prescription opioids are restricted substances, and 
prescription as well as distribution are strictly regulated 
and controlled by the government. Furthermore, it is 
illegal to promote restricted substances to the general 
public.
The present study has several limitations: first, data 
on medication were extracted from electronic patient 
charts available in only 42% of all cases, and therefore, 
there is a possibility of selection bias. However, our elec-
tronic records do not differentiate between missing data 
and simply not- scheduled medication, which is expected 
to be the case in a significant part of a population with 
a median age of 63 years. Second, patients taking non- 
prescription opioids or opioids on an as- needed basis 
could not be considered in the analysis as quantification 
of the actual daily dose was not possible. Missing data on 
non- opioid analgesics purchased over the counter and 
not reported by the patient remain unknown. In Swit-
zerland, common analgesics such as paracetamol and 
ibuprofen are available over the counter but only in a 
very limited quantity. Furthermore, the purchase is reim-
bursed by the insurance if prescribed by a physician, and 
we captured over the counter medication in our records 
as those are medically relevant. Third, under- reporting 
of adverse events of opioid therapy due to treatment by 
the primary care physician or another institution should 
be considered. Fourth, even though a large group of ED 
patients was investigated, our data stem from a single 
hospital and may not be generalisable to other settings 
in Switzerland or other European countries. Fifth, there 
is the possibility of residual confounding in retrospec-
tive studies. Sixth, no pilot testing of the data abstraction 
instrument was performed, abstractors were not blinded 
to the study hypothesis and there was no testing for inter- 
rater reliability. Seventh, it has to be noted that outcomes 
concerning the need for hospitalisation, 72- hour ED 
reconsultation, 30- day rehospitalisation and mortality are 
associations, and causality cannot be proven. Of course, 
opioid analgesics are often needed to treat pain and 
dyspnoea in patients with an underlying malignancy, who 
may have higher rates of adverse outcomes. However, 
it must be noted that in our study, only approximately 
20% of patients using opioids had an underlying malig-
nancy. Nevertheless, it cannot be excluded that adverse 
outcomes of opioid users can causally be attributed to 
Table 2 Prevalence and dosages of opioids
Patients, n (%)
Dose (mg), median 
(IQR)
Morphine equivalent 1906 (100) 30 (15–80.5)
Morphine 169 (8.9) 40 (20–160)
Hydromorphone 18 (0.9) 12 (8–16)
Transdermal fentanyl 401 (21.0) 0.6 (0.6–1.8)
Sublingual buprenorphine 19 (1.0) 6 (2–16)
Transdermal 
buprenorphine
18 (0.9) 0.84 (0.84–1.68)
Tramadol 316 (16.6) 100 (75–150)
Hydrocodeine 10 (0.5) 16.5 (10–30)
Codeine 130 (6.8) 60 (30–90)
Levomethadone 3 (0.2) 10 (10–10)
Methadone 118 (6.2) 80 (35–200)
Oxycodone 92 (4.8) 20 (15–30)
Oxycodone/naloxone 667 (35.0) 20 (10–40)
Tapentadol 102 (5.4) 150 (100–200)
Tilidine 1 (0.1) 150 (150–150)
Pethidine 3 (0.2) 50 (50–400)
Doses are given for the respective opioid. For oxycodone/naloxone, 
only the oxycodone dose was used. The conversion factors for the 
morphine equivalent calculation are as follows: hydromorphone, 4.5; 
transdermal fentanyl, 2.4; sublingual buprenorphine, 0.1; transdermal 
buprenorphine, 2.3; tramadol, 0.13; hydrocodeine, 0.13; codeine, 
0.13; levomethadone, 16; methadone, 8; oxycodone, 1.5; oxycodone 
naloxone, 1.5; tepentadole, 0.3, tilidine, 0.2; pethidine, 0.4.25
Table 3 Multivariate regression analysis of the impact of age, sex, intake of scheduled opioids and eGFR on mortality, 
readmission within 72 hours, rehospitalisation within 30 days and length of stay
OR (95% CI; p)
Mortality Readmission within 72 hours Rehospitalisation within 30 d
Length of stay 
(logarithmised), p value
Age 1.047 (1.036–1.059; <0.001) 0.989 (9.73–1.005; 0.17) 1.002 (0.994–1.009; 0.664) <0.001
Sex 1.651 (1.292–2.110; <0.001) 0.76 (0.454–1.272; 0.296) 1.109 (0.884–1.390; 0.371) 0.496
Opioid intake 2.916 (2.193–3.876; <0.001) 2.543 (1.224–5.283; 0.012) 3.630 (2.771–4.755; <0.001) <0.001
eGFR 0.980 (0.975–0.986; <0.001) 1.002 (0.990–1.014; 0.725) 0.986 (0.981–0.991; <0.001) <0.001
Mortality depicts in- hospital mortality only. GFR was chosen as a surrogate marker for comorbidity as we did not systematically abstract 
comorbidities.
eGFR, estimated glomerular filtration rate.
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their underlying disease, which might be the reason for 
opioid prescriptions. Lastly, kidney injury is not only 
expected to occur in advanced diabetes mellitus and 
arterial hypertension but also in heart failure23 and non- 
alcoholic fatty liver disease,24 many severe chronic condi-
tions do not impair kidney function. This is a limitation of 
our multivariate model where we used eGFR as the only 
marker for comorbidity.
In conclusion, the present study showed that prescrip-
tion opioid use is common and the prescription patterns 
are similar to those reported in the USA. However, as many 
as one in two patients did not have baseline non- opioid 
analgesia as recommended by the WHO ladder scheme. 
Opioid- related symptoms such as incoordination leading 
to falls, constipation and delirium were significantly more 
common in opioid users. Moreover, prescription opioid 
users were prone to need hospitalisation, reconsulted the 
ED within 72 hours and needed rehospitalisation within 
30 days.
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